Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant Melanoma
Background. Cutaneous malignant melanoma (CMM) is a heterogeneous disease, acknowledged for its lack of predictability regarding clinical evolution. In order to appreciate a patient’s individual prognosis, an attempt is made to find new tumor markers that parallel the disease progression. Objective....
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Skin Cancer |
| Online Access: | http://dx.doi.org/10.1155/2014/843214 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549650367774720 |
|---|---|
| author | Angela Sandru Eugenia Panaitescu Silviu Voinea Madalina Bolovan Adina Stanciu Sabin Cinca Alexandru Blidaru |
| author_facet | Angela Sandru Eugenia Panaitescu Silviu Voinea Madalina Bolovan Adina Stanciu Sabin Cinca Alexandru Blidaru |
| author_sort | Angela Sandru |
| collection | DOAJ |
| description | Background. Cutaneous malignant melanoma (CMM) is a heterogeneous disease, acknowledged for its lack of predictability regarding clinical evolution. In order to appreciate a patient’s individual prognosis, an attempt is made to find new tumor markers that parallel the disease progression. Objective. To identify if melanoma inhibitory activity (MIA) protein could represent a tool for selecting high risk early stages melanoma patients. Method. Between 2008 and 2013, 155 patients with CMM were treated in our clinic. 84 of them were classified into stages I and II, according to TNM 2009. MIA serum concentration was measured in all patients and 50 healthy donors. A cut-off value of 9.4 ng/ml was established using the ROC curve. Results. All patients were followed up by periodic investigations every 6 months. We have noticed that 66% of patients with MIA serum values at diagnosis greater than 9.4 ng/mL have relapsed, while only 5% of patients with MIA serum concentration below the estimated threshold, recurred during the follow-up period (P=0.000). The death risk was 12 times higher in pathological MIA group of patients (P=0.0001). Conclusions. Our data suggest that MIA is an independent prognostic factor for patients with localized CMM. |
| format | Article |
| id | doaj-art-501d6ed53d26481090c1860b885eece8 |
| institution | Kabale University |
| issn | 2090-2905 2090-2913 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Skin Cancer |
| spelling | doaj-art-501d6ed53d26481090c1860b885eece82025-02-03T06:10:51ZengWileyJournal of Skin Cancer2090-29052090-29132014-01-01201410.1155/2014/843214843214Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant MelanomaAngela Sandru0Eugenia Panaitescu1Silviu Voinea2Madalina Bolovan3Adina Stanciu4Sabin Cinca5Alexandru Blidaru6Department of Surgical Oncology, “Carol Davila” University of Medicine and Pharmacy, “Alexandru Trestioreanu” Oncologic Institute, Fundeni Street, No. 252, Sector 2, 022328 Bucharest, RomaniaDepartment of Medical Informatics and Biostatistics, “Carol Davila” University of Medicine and Pharmacy, Bucharest, RomaniaDepartment of Surgical Oncology, “Carol Davila” University of Medicine and Pharmacy, “Alexandru Trestioreanu” Oncologic Institute, Fundeni Street, No. 252, Sector 2, 022328 Bucharest, RomaniaDepartment of Carcinogenesis and Molecular Biology, “Alexandru Trestioreanu” Oncologic Institute, Bucharest, RomaniaDepartment of Carcinogenesis and Molecular Biology, “Alexandru Trestioreanu” Oncologic Institute, Bucharest, RomaniaDepartment of Carcinogenesis and Molecular Biology, “Alexandru Trestioreanu” Oncologic Institute, Bucharest, RomaniaDepartment of Surgical Oncology, “Carol Davila” University of Medicine and Pharmacy, “Alexandru Trestioreanu” Oncologic Institute, Fundeni Street, No. 252, Sector 2, 022328 Bucharest, RomaniaBackground. Cutaneous malignant melanoma (CMM) is a heterogeneous disease, acknowledged for its lack of predictability regarding clinical evolution. In order to appreciate a patient’s individual prognosis, an attempt is made to find new tumor markers that parallel the disease progression. Objective. To identify if melanoma inhibitory activity (MIA) protein could represent a tool for selecting high risk early stages melanoma patients. Method. Between 2008 and 2013, 155 patients with CMM were treated in our clinic. 84 of them were classified into stages I and II, according to TNM 2009. MIA serum concentration was measured in all patients and 50 healthy donors. A cut-off value of 9.4 ng/ml was established using the ROC curve. Results. All patients were followed up by periodic investigations every 6 months. We have noticed that 66% of patients with MIA serum values at diagnosis greater than 9.4 ng/mL have relapsed, while only 5% of patients with MIA serum concentration below the estimated threshold, recurred during the follow-up period (P=0.000). The death risk was 12 times higher in pathological MIA group of patients (P=0.0001). Conclusions. Our data suggest that MIA is an independent prognostic factor for patients with localized CMM.http://dx.doi.org/10.1155/2014/843214 |
| spellingShingle | Angela Sandru Eugenia Panaitescu Silviu Voinea Madalina Bolovan Adina Stanciu Sabin Cinca Alexandru Blidaru Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant Melanoma Journal of Skin Cancer |
| title | Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant Melanoma |
| title_full | Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant Melanoma |
| title_fullStr | Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant Melanoma |
| title_full_unstemmed | Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant Melanoma |
| title_short | Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant Melanoma |
| title_sort | prognostic value of melanoma inhibitory activity protein in localized cutaneous malignant melanoma |
| url | http://dx.doi.org/10.1155/2014/843214 |
| work_keys_str_mv | AT angelasandru prognosticvalueofmelanomainhibitoryactivityproteininlocalizedcutaneousmalignantmelanoma AT eugeniapanaitescu prognosticvalueofmelanomainhibitoryactivityproteininlocalizedcutaneousmalignantmelanoma AT silviuvoinea prognosticvalueofmelanomainhibitoryactivityproteininlocalizedcutaneousmalignantmelanoma AT madalinabolovan prognosticvalueofmelanomainhibitoryactivityproteininlocalizedcutaneousmalignantmelanoma AT adinastanciu prognosticvalueofmelanomainhibitoryactivityproteininlocalizedcutaneousmalignantmelanoma AT sabincinca prognosticvalueofmelanomainhibitoryactivityproteininlocalizedcutaneousmalignantmelanoma AT alexandrublidaru prognosticvalueofmelanomainhibitoryactivityproteininlocalizedcutaneousmalignantmelanoma |